Foghorn Therapeutics, Inc

Foghorn Therapeutics, Inc

Foghorn Therapeutics, Inc

Based in Cambridge, Massachusetts, Foghorn Therapeutics uses its proprietary Gene Traffic Control product platform to discover and develop drugs based on novel insights into the chromatin regulatory system, which directs gene expression in cells.
Founded
2016
Raised
$111M
Follow us
Alexa global traffic share
Latest funding
$61,000,000
Venture capital - 2019
$50,000,000
Venture capital - 2018
Flagship Ventures
Team Size
10+
Employees
$50,000,000 Venture capital
PE HUB

Flagship Pioneering provides $50 mln to Foghorn Therapeutics

Messaging
FinSMEs

Foghorn Therapeutics Raises $50M in Funding

Science Software development Health